Nonprofit · EIN 92-0240717
EVERY CURE INC
Tax-exempt · PHILADELPHIA, PA 19104
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2025 | 990 | $34,822,357 | $12,134,310 | $22,688,047 | $74,089,051 | $2,166,351 | $71,922,700 |
| December 31, 2024 | 990 | $54,466,208 | $7,434,417 | $47,031,791 | $51,613,641 | $2,337,747 | $49,275,894 |
Financial details: 990 for the year ended December 31, 2025
Revenue
- Contributions, gifts and grants
- $33,527,421
- of which government grants
- $15,887,226
- Program service revenue
- $0
- Investment income
- $1,294,936
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $2,787,334
- Compensation of officers, directors and key employees
- $1,525,128
- Other salaries and wages
- $3,865,458
- Salaries, compensation and benefits (total)
- $6,263,984
- Professional fundraising fees
- $0
- Legal fees
- $273,920
- Occupancy
- $290,504
- Travel
- $324,212
- Depreciation
- $28,309
- Program services (functional)
- $9,157,827
- Management and general (functional)
- $2,210,827
- Fundraising (functional)
- $765,656
Balance sheet and other
- Total assets, start of year
- $51,613,641
- Total assets, end of year
- $74,089,051
- Total liabilities, end of year
- $2,166,351
- Net assets, end of year
- $71,922,700
- Land, buildings and equipment
- $46,731
- Publicly traded securities
- $4,206,426
- Net assets without donor restrictions
- $42,262,863
- Net assets with donor restrictions
- $29,659,837
- Gross receipts
- $34,822,357
- Employees
- 37
- Volunteers
- 39
- Year formed
- 2022
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2025, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| ALEXANDER PAMPALONE | CHIEF PHILANTHROPY OFFICER Officer | 40 | $336,749 | $28,971 |
| MARY ZUCCATO | CHIEF OPERATING OFFICER Officer | 40 | $277,841 | $27,186 |
| CHARLOTTE HEMPSTEAD | CHIEF PLATFORM OFFICER Officer | 40 | $244,175 | $46,158 |
| MATTHEW GODDEERIS | CHIEF SCIENTIFIC OFFICER Officer | 40 | $238,598 | $22,652 |
| LEE LANCASHIRE | HEAD OF DATA SCIENCE Highest-paid employee | 40 | $204,294 | $35,444 |
| PASCAL BROKMEIER | HEAD OF ENGINEERING Highest-paid employee | 40 | $189,683 | $27,687 |
| DAVID FAJGENBAUM | CO-FOUNDER & PRESIDENT Trustee or director, Officer | 40 | $204,042 | $4,080 |
| LAURENS VIJNCK | PRINCIPAL DATA ENGINEER Highest-paid employee | 40 | $135,235 | $27,601 |
| ELLIOTT SHARP | DIRECTOR, PIPELINE STRATEGY Highest-paid employee | 40 | $129,821 | $22,653 |
| VANESSA ROSTICK | DIRECTOR OF HR Highest-paid employee | 40 | $134,310 | $14,321 |
| GRANT MITCHELL | FORMER CEO & TREASURER Trustee or director, Officer | 40 | $88,720 | $5,956 |
| TANIA SIMONCELLI | VICE CHAIR & SECRETARY Trustee or director, Officer | 1 | $0 | $0 |
| FREDA LEWIS-HALL | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JULIAN BAKER | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ROBERT MCDONALD | DIRECTOR Trustee or director | 1 | $0 | $0 |
2 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| JANET WOODCOCK | DIRECTOR Trustee or director | 1 | $0 |
| ERIC HORVITZ | DIRECTOR Trustee or director | 1 | $0 |
990 for the year ended December 31, 2024: 14 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| GRANT MITCHELL | CO-FOUNDER,CEO (COMP 9/23-12/24) Trustee or director, Officer | 40 | $448,117 | $17,412 |
| DAVID FAJGENBAUM | PRESIDENT (COMP 9/23-12/24) Trustee or director, Officer | 30 | $326,793 | $0 |
| MARY ZUCCATO | COO (COMP 2/24-12/24) Officer | 40 | $198,737 | $22,827 |
| CHARLIE HEMPSTEAD | VP OF PLATFORM (COMP 4/24-12/24) Key employee | 40 | $172,819 | $29,541 |
| RICHARD JUDE RIESE | CMO (COMP 7/24-11/24) Highest-paid employee | 40 | $141,805 | $19,170 |
| ADAM GREEN | CHIEF OF STAFF (COMP 2/24-12/24) Highest-paid employee | 40 | $108,000 | $1,938 |
| TANISHA CARINO | VICE CHAIR Trustee or director, Officer | 2 | $0 | $0 |
| TRACEY SIKORA | CO-FOUNDER, SECRETARY (THRU 2024) Trustee or director, Officer | 15 | $0 | $0 |
| ROBERT BATTISTA | TREASURER (THRU 2024) Trustee or director, Officer | 2 | $0 | $0 |
| FREDA LEWIS-HALL | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ROBERT MCDONALD | DIRECTOR Trustee or director | 1 | $0 | $0 |
| TANIA SIMONCELLI | DIRECTOR Trustee or director | 1 | $0 | $0 |
| ERIC HORVITZ | DIRECTOR Trustee or director | 2 | $0 | $0 |
| JANET WOODCOCK | DIRECTOR Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 3675 MARKET ST STE 200, PHILADELPHIA, PA 19104-2897
- In care of
- % GRANT W MITCHELL
- Principal officer (990 for 2025)
- DAVID FAJGENBAUM, 3675 MARKET ST SUITE 200, PHILADELPHIA, PA 19104
- Signed the 990
- DAVID FAJGENBAUM, CEO
- Phone
- (484) 285-6568
- Return prepared by
- SAX ADVISORS LLC
Mission
EVERY CURE IS ON A MISSION TO SAVE AND IMPROVE LIVES BY REPURPOSING DRUGS, UTILIZING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING TO SYSTEMATICALLY SCAN THE WORLD'S BIOMEDICAL KNOWLEDGE ACROSS ALL APPROVED DRUGS AND ALL KNOWN DISEASES TO IDENTIFY THE MOST PROMISING OPPORTUNITIES. THE ORGANIZATION'S MEDICAL TEAM OF PHYSICIANS AND RESEARCHERS EVALUATES AND VALIDATES THESE OPPORTUNITIES AND ADVANCES THE MOST PROMISING CANDIDATES THROUGH LABORATORY STUDIES AND CLINICAL TRIALS TO ENSURE EFFECTIVE THERAPIES REACH PATIENTS IN NEED.
Program accomplishments
- AI TOOL DEVELOPMENT: IN 2025, EVERY CURE'S TECHNICAL TEAM CONTINUED TO BUILD AND ENHANCE ITS AI-PLATFORM TO SYSTEMATICALLY IDENTIFY HIGH-POTENTIAL DRUG REPURPOSING OPPORTUNITIES. THE TEAM DEVELOPED AND TESTED THREE MAIN METHODS OF RANKING REPURPOSING OPPORTUNITIES AT SCALE: GRAPH-BASED MODELING OF BIOLOGICAL AND CLINICAL RELATIONSHIPS, EXTRACTION OF EXISTING SCIENTIFIC EVIDENCE, AND ANALYSIS OF REAL-WORLD PATIENT DATA. TOGETHER, THESE APPROACHES GENERATED APPROXIMATELY 1,400 CANDIDATE DRUG REPURPOSING OPPORTUNITIES EACH MONTH FOR CLINICAL REVIEW BY EVERY CURE'S MEDICAL TEAM, SUBSTANTIALLY EXPANDING THE PIPELINE OF POTENTIAL REPURPOSED TREATMENTS THAT CAN BE EVALUATED TO SAVE AND IMPROVE PATIENTS' LIVES.Expenses $6,949,376 · grants $2,787,334
- DRUG REPURPOSING RESEARCH AND DEVELOPMENT (SCIENTIFIC APPLICATION): AT THE END OF 2025, EVERY CURE HAD NINE ACTIVE DRUG REPURPOSING PROGRAMS SPANNING FROM ULTRA RARE TO COMMON DISEASES, UP FROM 5 IN 2024. SELECTION OF THE MOST PROMISING DRUG REPURPOSING OPPORTUNITIES FOR FURTHER ADVANCEMENT INVOLVES MEDICAL EXPERTS EVALUATING EXISTING KNOWLEDGE AND AI-GENERATED INSIGHTS. ADVANCEMENT OF THESE PROMISING REPURPOSING OPPORTUNITIES FROM DISCOVERY TO PATIENT IMPACT INCLUDES ACTIVITIES SUCH AS MANAGING PRE-CLINICAL STUDIES, REVIEWING REAL-WORLD EVIDENCE, PERFORMING CLINICAL TRIALS, AND DISSEMINATING KNOWLEDGE TO ENSURE ADOPTION.Expenses $2,056,461
- EDUCATION AND AWARENESS-RAISING ON DRUG REPURPOSING: EVERY CURE EDUCATES PHYSICIANS, RESEARCHERS, PATIENTS, POLICYMAKERS, AND THE GENERAL PUBLIC ABOUT THE POTENTIAL FOR DRUG REPURPOSING TO ACCELERATE CURES. EDUCATION AND OUTREACH ARE CENTRAL TO CREATING A SHIFT IN DRUG DISCOVERY AND THE PRACTICE OF MEDICINE, WHERE EXISTING THERAPIES ARE FULLY LEVERAGED FOR DISEASES BEYOND THEIR ORIGINAL APPROVALS. IN 2025, WE REACHED MILLIONS OF PEOPLE WITH OUR MISSION THROUGH SOCIAL MEDIA AND PRESS COVERAGE, INCLUDING A TED TALK BY OUR FOUNDER, HIGHLIGHTING THE STORY OF DRUG REPURPOSING AND EVERY CURE'S MISSION WHICH INCREASED VISIBILITY AND ENGAGEMENT WITH OUR WORK. WE HAVE DISSEMINATED SCIENTIFIC FINDINGS THROUGH PRESENTATIONS AT INTERNATIONAL SCIENTIFIC MEETINGS, INVITED TALKS AT RESEARCH INSTITUTIONS, AND PUBLICATION OF EDUCATIONAL CONTENT IN PROFESSIONAL OUTLETS TO INCREASE AWARENESS AMONG PHYSICIANS AND SCIENTISTS. THESE EDUCATIONAL ACTIVITIES INCREASED AWARENESS OF DRUG REPURPOSING AMONG HEALTHCARE PROFESSIONALS, RESEARCHERS, POLICYMAKERS, PATIENTS, AND THE PUBLIC, HELPING TO FOSTER COLLABORATION AND SUPPORT THE RESPONSIBLE ADVANCEMENT OF DRUG REPURPOSING ACROSS THE HEALTHCARE ECOSYSTEM.Expenses $151,990
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | 990 on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 92-0240717
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2023
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H99)
- Assets (IRS master file)
- $74,089,051
- Income (IRS master file)
- $34,822,357
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2025 | – | – | – | IRS |
| 990 | December 2024 | – | – | – | IRS |
| 990 | December 2023 | $2,443,385 | $452,802 | $3,270,374 | IRS |
| 990 | December 2022 | $316,125 | $1,685 | $314,440 | IRS |
990-N: the IRS publishes only the latest e-Postcard per organization; earlier years appear here as 990.tax collects the monthly files. 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS.
Questions about EVERY CURE INC
- What is the EIN of EVERY CURE INC?
- The employer identification number (EIN) of EVERY CURE INC is 92-0240717.
- Is EVERY CURE INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2023.
- Are donations to EVERY CURE INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does EVERY CURE INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of EVERY CURE INC due?
- The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did EVERY CURE INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2025.
- Who is the principal officer of EVERY CURE INC?
- The 990 for the year ended December 31, 2025 names DAVID FAJGENBAUM.
- Who are the officers and directors of EVERY CURE INC?
- The 990 for the year ended December 31, 2025 lists 17 people; 11 received compensation from the organization, the highest $336,749 (ALEXANDER PAMPALONE, CHIEF PHILANTHROPY OFFICER).
- How much revenue does EVERY CURE INC have?
- On its 990 for the year ended December 31, 2025 it reported revenue of $34,822,357, expenses of $12,134,310 and total assets of $74,089,051 at year end.
Other nonprofits in PHILADELPHIA
- AMERICAN ASSOCIATION FOR CANCER RESEARCH EIN 23-6251648 · last filed 990 for 2025
- INSTITUTE FOR CANCER RESEARCH EIN 23-6296135 · last filed 990 for 2025
- THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY EIN 23-6434390 · last filed 990 for 2025
- PHILADELPHIA FIGHT EIN 23-2625934 · last filed 990 for 2025
- WILLS EYE OPHTHALMOLOGY CLINIC INC EIN 23-3065896 · last filed 990 for 2025
- MONELL CHEMICAL SENSES CENTER EIN 23-2020897 · last filed 990 for 2025
- COALITION OF CANCER COOPERATIVE GROUPS EIN 23-2935628 · last filed 990 for 2025
- NATIONAL DISEASE RESEARCH INTERCHANGE EIN 23-2213205 · last filed 990 for 2025
All nonprofits in PHILADELPHIA · Pennsylvania · Medical research